Vorinostat is a histone deacetylase inhibitor (HDACi) that suppresses HDAC6 expression, thereby disrupting the ARID1A6488delG/HDAC6/IL-10 signaling pathway implicated in endometriosis-associated ovarian carcinoma (EAOC). This evidence concerns the gene HDAC6 and endometriosis.